MAP2K7 and non-small cell lung carcinoma: Dual MAPK pathway inhibition using dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) achieved a 64% response rate and a median progression-free survival (PFS) of 10.9 months in BRAF V600 mutation-positive NSCLC [5], and the combined treatment was approved by the Food and Drug Administration (FDA) in 2017 [6].